Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist
- 1 October 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 137 (4) , 449-458
- https://doi.org/10.1038/sj.bjp.0704887
Abstract
1. Human urotensin-II (hU-II), a cyclic undecapeptide, is amongst the most potent mammalian vasoconstrictors identified, suggesting that hU-II and its G-protein-coupled receptor (UT) may regulate cardiovascular homeostasis. Such a hypothesis would benefit greatly from the development of selective UT antagonists. 2. Although the somatostatin (SST) antagonist SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide) is purported to block U-II-induced contractions in rat isolated aorta, little is known about its specific pharmacological properties. 3. SB-710411 (10 micro M) inhibited hU-II-induced contraction in rat isolated aorta causing a significant, parallel shift in the agonist concentration-response curve (pK(b) 6.28+/-0.11; n=8) with no suppression of the E(max). In contrast, SB-710411 did not alter the contractile actions of angiotensin-II, phenylephrine, or KCl. Paradoxically, however, SB-710411 potentiated the contractile response to endothelin-1 (pEC(50) 8.02+/-0.16 and 8.54+/-0.11, P<0.01; n=8). Rather than being specific toSB-710411, this phenomenon appears to be related to somatostatin receptor affinity and not intrinsic activity since the SST agonist somatostatin-14 and antagonist cyclo-somatostatin also potentiated endothelin-1-induced contraction. 4. SB-710411 (10 micro M) did not inhibit carbachol, sodium nitroprusside, IBMX, isoprenaline, and levcromakalim-induced reversal of tone established with noradrenaline. In contrast, however, SB-710411 significantly inhibited the reversal of tone established with endothelin-1 using the same vasorelaxants. 5. In summary, although SB-710411 inhibits the vasoconstrictor actions of hU-II in a competitive, surmountable manner, it also possesses additional pharmacological actions. Thus, whilst the present study is amongst the first to detail the properties of a functional U-II receptor antagonist, the data suggest caution be used when assessing data generated utilizing this moiety and other SST analogues.Keywords
This publication has 18 references indexed in Scilit:
- Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonistsEuropean Journal of Pharmacology, 2002
- Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive ratsJournal of Hepatology, 2002
- Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agentsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2002
- Urotensin II evokes potent vasoconstriction in humans in vivoBritish Journal of Pharmacology, 2002
- Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal ratsFEBS Letters, 2001
- Cardiostimulant effects of urotensin‐II in human heart in vitroBritish Journal of Pharmacology, 2001
- Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkeyBritish Journal of Pharmacology, 2000
- Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivityRegulatory Peptides, 2000
- Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1British Journal of Pharmacology, 2000
- Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous veinBritish Journal of Pharmacology, 1995